GlassScriptPhysician profile
Ryan R Falsey
NPI 1386871523
$17,317.15
in general payments reported to CMS, 2019-2025
24 companies · $718 in 2025
The $718 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $7,837 · 2021: $135 · 2022: $2,230 · 2023: $586 · 2024: $5,525 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,320 · Food and Beverage: $2,220 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,320.00 |
| Food and Beverage | $2,219.88 |
| Education | $288.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,700.03 | 2019-2025 | |
| Leo Pharma INC. | $1,701.85 | 2022-2025 | Adbry |
| Abbvie INC. | $1,134.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $375.13 | 2019-2025 | |
| Janssen Biotech, INC. | $357.80 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $185.49 | 2023-2025 | Zoryve |
| Amgen INC. | $182.98 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $175.96 | 2021-2024 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $161.86 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $58.50 | 2019-2025 | Nemluvio |
| Dermavant Sciences, INC. | $45.26 | 2023-2024 | Vtama |
| Genzyme Corporation | $29.12 | 2021-2022 | |
| Lilly USA, LLC | $23.62 | 2025 | Ebglyss |
| Dusa Pharmaceuticals, INC. | $23.14 | 2019 | |
| Almirall LLC | $19.65 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.34 | 2020 | |
| Organon LLC | $16.11 | 2025 | |
| Medtronic, INC. | $15.94 | 2024 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2025 | Spevigo |
| Encore Dermatology INC. | $14.75 | 2019 | |
| Botanix Sb INC | $14.59 | 2025 | Sofdra |
| Biofrontera INC. | $14.43 | 2019 | |
| Verrica Pharmaceuticals INC. | $13.94 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Falsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.